Lilly Asia Ventures returned to take part in a series B round led by Access Industries unit Access Biotechnology that took Passage Bio's funding to $226m to date.
US-based genetic medicine developer Passage Bio completed a $110m series B round yesterday led by Access Biotechnology, the life sciences investment vehicle for diversified conglomerate Access Industries.
Lilly Asia Ventures, a corporate venturing subsidiary of pharmaceutical firm Eli Lilly, also took part, as did OrbiMed, Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital, Boxer Capital, Highline Capital Management, Logos Capital and Sphera Funds Management.
Founded in 2018, Passage Bio is developing therapies to treat rare monogenic diseases…
